Sales Strategies, Upcoming Financial Results Schedules, Clinical Study Updates, and FDA Agreements - Research Report on Arena,

    Sales Strategies, Upcoming Financial Results Schedules, Clinical Study
  Updates, and FDA Agreements - Research Report on Arena, Seattle Genetics,
                         Halozyme, Insmed, and Omeros

PR Newswire

NEW YORK, October 21, 2013

NEW YORK, October 21, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Arena
Pharmaceuticals, Inc. (NASDAQ: ARNA), Seattle Genetics Inc. (NASDAQ: SGEN),
Halozyme Therapeutics, Inc. (NASDAQ: HALO), Insmed Incorporated (NASDAQ:
INSM), and Omeros Corporation (NASDAQ: OMER). Today's readers may access these
reports free of charge - including full price targets, industry analysis and
analyst ratings - via the links below.

Arena Pharmaceuticals, Inc. Research Report

On October 15, 2013, Arena Pharmaceuticals, Inc. (Arena) reported that Eisai
Inc. will increase its BELVIQ^® (a drug approved by the US Food and Drug
Administration for chronic weight management) sales-force to approximately 400
representatives by December 2013. The Company stated that Eisai Inc. is
responsible for the marketing and distribution of BELVIQ in the United States
under its agreement with Arena. According to Arena, this move will double the
size of the sales-force from when BELVIQ became available in June 2013 and
enable Eisai to reach approximately 65,000 physicians in the US, including
primary care providers, endocrinologists, cardiovascular specialists, and
gastrointestinal specialists.Jack Lief, Arena's President and CEO, stated,
"We have seen increasing physician interest in BELVIQ as an important
treatment option for chronic weight management, the payor landscape has
improved and we are encouraged by the early response to the patient support
programs and recently launched patient campaign. Eisai's efforts have led to
month over month increases in BELVIQ prescriptions to date, and we expect that
the expansion of the BELVIQ sales force will help communicate the safety and
efficacy of BELVIQ to an increased number of physicians." The Full Research
Report on Arena Pharmaceuticals, Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.AnalystsCorner.com/r/full_research_report/6a95_ARNA]

--

Seattle Genetics Inc. Research Report

On October 15, 2013, Seattle Genetics Inc. (Seattle Genetics) announced that
it will report its financial results for Q3 2013 after the markets close on
Tuesday, November 5, 2013. Seattle Genetics reported that it will hold its Q3
2013 conference call and webcast on the same day at 1:30 p.m. PT (4:30 p.m.
ET) to discuss the results and provide a general corporate update. Also, the
live webcast and its replay will be available on the Company's website through
the Investors and News section. The Full Research Report on Seattle Genetics
Inc. - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/ff98_SGEN]

--

Halozyme Therapeutics, Inc. Research Report

On October 15, 2013, Halozyme Therapeutics, Inc. (Halozyme) announced that the
first patient has been dosed in a closed loop control ("artificial pancreas")
clinical study involving the Company's recombinant human hyaluronidase. The
Company informed that the study is being performed by researchers at Yale
School of Medicine in patients with type 1 diabetes. According to Halozyme,
the study will compare blood glucose control observed when using lispro
(marketed as Humalog^®), a rapid acting analog insulin, alone versus using
hyaluronidase in combination with lispro in two different administration
formats. Commenting on the clinical study, Gregory I. Frost, Ph.D., President
and CEO of Halozyme, stated, "We are pleased that Yale investigators received
grant funding from JDRF to independently test our enzyme in this important
research to advance insulin therapy for patients in need. We look forward to
the results of this novel study." The Full Research Report on Halozyme
Therapeutics, Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/ea1b_HALO]

--

Insmed Incorporated Research Report

On October 15, 2013, Insmed Incorporated (Insmed) announced the completion of
patient enrollment in its Phase 2 clinical study of ARIKACE^®, or liposomal
amikacin for inhalation, for patients with recalcitrant nontuberculous
mycobacterial (NTM) lung disease in the US and Canada. Insmed informed that
ARIKACE has received Orphan Drug, Qualified Infectious Disease Product (QIDP),
and Fast Track designations from the US Food and Drug Administration (FDA) for
the treatment of NTM lung infections. Further, the Company announced that it
has initiated the Scientific Advice Working Party (SAWP) process with the
European Medicines Agency (EMA) and expects to have discussions with the EMA
regarding ARIKACE for NTM lung disease during Q4 2013. Insmed stated that it
is also in the process of evaluating other international markets, such as
Japan, where NTM lung infections are already a growing unmet medical need. The
Full Research Report on Insmed Incorporated - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.AnalystsCorner.com/r/full_research_report/9c5b_INSM]

--

Omeros Corporation Research Report

On October 15, 2013, Omeros Corporation (Omeros) announced that the US Food
and Drug Administration (FDA) has confirmed its agreement with the Pediatric
Study Plan (PSP) proposed by Omeros to study the use of OMS302 in pediatric
patients undergoing primary cataract extraction. Omeros informed that the FDA
has issued a Written Request consistent with the PSP, meaning that successful
completion of the PSP would make OMS302 eligible for an additional six months
of marketing exclusivity in the US. Commenting on the development, Gregory A.
Demopulos, M.D., Chairman and CEO of Omeros, stated, "With FDA's Written
Request and agreement on our Pediatric Study Plan, we now have clear paths
forward to obtain additional marketing exclusivity for our drug in both the
U.S. and Europe. We look forward to making OMS302 available to ophthalmic
surgeons and their patients in these major markets next year." The Full
Research Report on Omeros Corporation - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.AnalystsCorner.com/r/full_research_report/e3c9_OMER]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we
    are only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Namrata Maheshwari,
CFA, has only reviewed the information provided by Equity News Network in this
article or report according to the Procedures outlined by Equity News Network.
Equity News Network is not entitled to veto or interfere in the application of
such procedures by the outsourced provider to the articles, documents or
reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

AnalystsCorner.com

SOURCE Analysts' Corner

Contact: CONTACT PERSON: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North
America)
 
Press spacebar to pause and continue. Press esc to stop.